Whole uteri were collected on days 1, 4, and 8 of pregnancy and from ovariectomized mice injected with vehicle, progesterone, or 17β-estradiol...The Atg9 isoforms exhibited distinct subcellular localizations in UECs and may play different roles in autophagy. Notably, human uterine cells exhibited reduced ATG9B expression, suggesting that this suppression may be due to epigenetic regulation.

P=N/A, N=75, Recruiting, Women's Hospital School Of Medicine Zhejiang University

P4, N=60, Recruiting, University of Kansas Medical Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

P=N/A, N=90, Recruiting, University of Udine

The use of drug combinations, such as 9cUAB130 with carboplatin and cisplatin with TAC-101, shows enhanced cytotoxic effects and reductions in ovarian tumor volume compared to single-drug treatments. Combining cisplatin with calcitriol and progesterone increases VDR expression, potentially enhancing the effectiveness of anticancer therapy in ovarian cancer...A balanced daily intake of vitamins is important, as both deficiency and excess can influence cancer development. It has been observed that there is a U-shaped relationship between group B vitamins and metabolic markers and clinical outcomes.

No abstract available

To block implantation factors, progesterone knockout (PKO) tdT mice were created...In conclusion, endometrial derived implantation factors, such as LIF, are necessary to initiate ectopic tissue growth. We have developed an animal model of ectopic growth of gynecologic tissues in a WT mouse which will potentially allow for development of new prevention and treatment modalities.

P2, N=8, Recruiting, UNC Lineberger Comprehensive Cancer Center | Suspended --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Sep 2024 --> Jun 2025

P4, N=40, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2024 --> Jun 2027 | Trial primary completion date: Dec 2023 --> Dec 2026

P4, N=110, Completed, IRCCS San Raffaele | Active, not recruiting --> Completed

Future clinical studies are essential to confirm the safe dose of royal jelly as an adjuvant therapy in breast cancer.

P=N/A, N=255, Active, not recruiting, University of Utah | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> Dec 2024

Retrospective cohort study collected data for patients with AEH or EMCA who had an endometrial sample after receiving conservative therapy utilizing either Megestrol acetate or Levonorgestrel Intrauterine device (IUD). Immunohistochemistry (IHC) was performed on pre- and post- treatment biopsy samples to assess androgen receptor (AR), estrogen receptor (ER), and progesterone receptor (PR) expression...Patients who successfully responded to the treatment demonstrated a significantly greater decrease in IHC scores after the treatment compared to those who did not respond (p = 0.009). Steroid receptor expression could be used as a possible biomarker for response to progestin therapy in patients undergoing conservative management for AEH and EMCA.

EAH patients with MMR-d and p53abn have a significantly higher risk of disease relapse and progression. Thus, MMR-d and p53abn may be used as predictive biomarkers of progestin resistance and endometrial tumorigenesis in EAH.

P4, N=110, Active, not recruiting, IRCCS San Raffaele | Not yet recruiting --> Active, not recruiting | Trial completion date: Feb 2023 --> Apr 2024 | Trial primary completion date: Aug 2022 --> Feb 2024

We conducted a migration assay, invasion assay, and MTT assay using dienogest and medroxyprogestrone acetate. Our results suggest that KRAS mutation and PIK3CA mutation in endometriotic cells may not be associated with progesterone resistance in terms of aggressiveness. However, KRAS mutations may be associated with progesterone resistance in the context of pain.

This shows the potential neuroprotective effect of progesterone against glioma due to its influence on EGFR expression and other signaling pathways. Aside from these, several experimental and approved drug candidates were also identified, which include an adrenergic receptor antagonist, a PPAR-γ receptor agonist, a CDK inhibitor, a sodium channel blocker, a bradykinin receptor antagonist, and a dopamine receptor agonist, which further highlights the gene network as a potential therapeutic avenue for glioma.

Notably, hormonal administration of diethylstilbestrol (DES) or progesterone (P4) upregulated oviduct-specific genes in these cells...The established immortalized cOECs overcome previous challenges associated with long-term culture and maintenance, providing a reliable platform for efficient protein production validation. This study presents a comprehensive characterization of the immortalized cOECs, addressing critical limitations associated with in vivo systems and laying a foundation for the development of a streamlined and effective chicken bioreactor model.

P2, N=104, Recruiting, Fudan University | Trial primary completion date: Mar 2024 --> Mar 2025

P=N/A, N=60, Not yet recruiting, University of the Philippines

P4, N=93, Completed, Thomas Jefferson University | Recruiting --> Completed | Phase classification: PN/A --> P4 | N=206 --> 93 | Trial completion date: Dec 2025 --> Feb 2024 | Trial primary completion date: Jun 2025 --> Feb 2024

Lymph node metastasis (2.43 [1.28-4.63]), large tumor size (1.80 [1.24-2.62]), and high histological grade (2.02 [1.44-2.84]) were also risk factors for overall survival, and high progesterone status was a possible favorable prognostic factor for BCSS (0.20 [0.10-0.42]). Identified risk factors were consistent with the previous reports, and this study provides quantitative summary of risk factors for HR+/HER2- early breast cancer recurrence in Japan. (PROSPERO Registration ID, CRD42022338391.).

P=N/A, N=34, Not yet recruiting, University of Colorado, Denver

Recreational physical activity was associated with lower breast cancer risk in both pre- and postmenopausal women, supporting recreational physical activity as an accessible, modifiable exposure associated with reduced breast cancer risk regardless of menopausal status.

P=N/A, N=200, Completed, IVI Madrid | Phase classification: P4 --> P=N/A

Surface Plasmon Resonance (SPR) analysis revealed a strong interaction between PRO and pCTS-L (KD = 78.2 ± 33.7 nM), which was paralleled with a positive correlation between serum PRO concentration and serum pCTS-L level (ρ = 0.56, P = 0.0009) or disease severity (Sequential Organ Failure Assessment, SOFA; ρ = 0.64, P = 0.0001) score in septic patients. Our observations support a promising opportunity to explore DM-β-CD nanoparticles entrapping lipophilic drugs as possible therapies for clinical sepsis.

Using an established human primary cell culture model, we previously demonstrated that the promyelocytic leukemia zinc finger (PLZF) transcription factor is a direct target of the progesterone receptor (PGR) and is essential for progestin-dependent decidualization of human endometrial stromal cells (HESCs)...In addition to a defect in P4-dependent receptivity, the Plzf d/d endometrium fails to undergo decidualization in response to an artificial decidual stimulus, providing the in vivo validation for our earlier HESC culture findings. Collectively, our new Plzf d/d mouse model underscores the physiological importance of the PLZF transcription factor not only in endometrial stromal cell decidualization but also uterine receptivity, two uterine cellular processes that are indispensable for the establishment of pregnancy.

P3, N=500, Active, not recruiting, AbbVie | Phase classification: P3b --> P3 | Trial primary completion date: Aug 2023 --> Jul 2024

CD82/KAI1 expression showed a significant time-dependent increase in cultured stromal cells after 24 and 48 h of progesterone (P4) and estrogen (E2) treatment...Meanwhile, there was an attenuated expression of CD82/KAI1 due to an adenovirus siRNA knockdown, whereas cyclin D3 and PR expressions were not affected. Our findings suggest a potential role of CD82/KAI1 in regulating the process of decidualization, providing insights into stromal cell differentiation.

P4, N=653, Recruiting, Northwestern University | Trial completion date: Oct 2023 --> Apr 2024 | Trial primary completion date: Oct 2023 --> Apr 2024

P4, N=120, Completed, University of Palermo

P2, N=0, Withdrawn, Mount Sinai Hospital, Canada | N=80 --> 0 | Unknown status --> Withdrawn

P4, N=103, Completed, University of Palermo

P=N/A, N=591, Terminated, Instituto Valenciano de Infertilidad, IVI VALENCIA | N=1200 --> 591 | Active, not recruiting --> Terminated; under-recruitment

P2, N=38, Enrolling by invitation, Mayo Clinic | Recruiting --> Enrolling by invitation

P1/2, N=57, Active, not recruiting, National Institute of Environmental Health Sciences (NIEHS) | Recruiting --> Active, not recruiting | N=570 --> 57

P4, N=22, Recruiting, University of Pennsylvania | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

P=N/A, N=200, Not yet recruiting, University of Utah | N=40 --> 200 | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Aug 2026

In conclusion, our study has provided some solid basis for BMP1 to be used as a reliable common biomarker for BLCA, KIRC, and LUAD patients.

Our study demonstrates that screen-detected invasive breast cancers had more favourable tumour characteristics than non-screen-detected after adjusting for age, year and county of diagnosis, and even after adjusting for T and N. The trend towards favourable tumour characteristics was less pronounced in the 40-49 age group compared to the other age groups, except for ER and PgR.

P3, N=1020, Active, not recruiting, Myovant Sciences GmbH | Trial completion date: Apr 2025 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2025

P3, N=680, Recruiting, IBSA Institut Biochimique SA | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Feb 2024 --> Sep 2024